Aurora Cannabis reported a 7% increase in total net revenue to $94.2 million for Q3 2026, primarily driven by a record 12% growth in global medical cannabis net revenue to $76.2 million. The company achieved an adjusted EBITDA of $18.5 million and generated $15.5 million in free cash flow, while maintaining a strong balance sheet with $154.4 million in cash and short-term investments.
Total net revenue increased by 7% year-over-year to $94.2 million.
Global medical cannabis net revenue reached a record $76.2 million, up 12% from the prior year.
Adjusted EBITDA stood at $18.5 million, reflecting a 20% sequential increase.
The company generated $15.5 million in free cash flow and maintained a debt-free cannabis business.
For the full fiscal year 2026, Aurora Cannabis expects continued growth in global medical cannabis revenue and adjusted EBITDA, driven by strategic focus on high-margin opportunities and operational efficiencies.
Analyze how earnings announcements historically affect stock price performance